HIPP TECHNOLOGY GROUP acquired by DEUTSCHE BETEILIGUNGS (DBAG)

The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors. The primary rationale behind the deal is the creation of a comprehensive "One-Stop-Shop" offering for global orthopedic clients, combining Céfiméca’s specialized expertise in precision implants with Oury Medical’s established strength in surgical instrumentation

In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period. The transaction is fundamentally designed to facilitate the intergenerational transmission of the family-owned enterprise from founder Jacques Mignot to his son, Diego Mignot, who officially assumes the presidency

Siparex has reaffirmed its commitment to Winncare by leading a quaternary LBO to retain control of the medical device manufacturer. This transaction allows Siparex, which originally acquired the company in 2021 via its ETI 5 fund, to extend the maturity of its investment while slightly increasing its ownership stake alongside the management team led by President Laurent Faugères. The deal marks a significant restructuring of the minority capital: IDI, which had been an investor since 2014, and Capza have both exited their positions

Lone Star Funds has entered into a definitive agreement to acquire a majority stake in Lonza Group’s Capsules & Health Ingredients (CHI) division. Lonza will retain a 40% equity position in the newly independent business, ensuring industrial continuity and shared upside in the future growth of the platform. The strategic rationale for Lonza is the completion of its long-term transformation into a "pure-play" CDMO (Contract Development and Manufacturing Organization). For CHI, the transition to a standalone entity under Lone Star’s control is designed to enhance its strategic agility and provide the dedicated capital necessary to accelerate innovation in plant-based capsules and nutritional ingredients

The acquisition of Resolution Medical by Resonetics signifies a major step in the group’s expansion toward a comprehensive, full-lifecycle service model. The strategic rationale for this transaction centers on an "integrated-platform" maneuver, merging the target’s technical operational depth in biosimulation and cleanroom assembly with the acquirer’s established scale in laser-based component manufacturing and battery systems. This structural alignment provides the organization with the scientific talent and technological hardware necessary to manage the increasing technical complexity of neuromodulation and structural heart devices

NORD Holding have acquired Hallmarq Veterinary Imaging from August Equity to merge it with German-based OR Technology. The transaction establishes a new, globally active imaging technology holding company in the veterinary sector. This is the second acquisition by NORD Holding in this sector in less than a year, following its partnership with OR Technology in 2025. The strategic rationale is to create a "one-stop-shop" for veterinary imaging, combining Hallmarq's specialized MRI/CT expertise with OR Technology’s digital X-ray and ultrasound portfolio

CIMG, through its subsidiary DZR, signed an agreement to acquire 100% of Daren Technology for approximately $40M in stock. The transaction features a highly structured Phased Payment consideration (6%, 14%, 28%, and 52%) released over 3.5 years. This earn-out structure is strictly tied to Daren achieving aggressive audited revenue targets, starting at $29M in 2026 and scaling to $257M by September 2029. This structure ensures alignment between the acquisition cost and the realized growth of the target's biopharmaceutical activities

IMA Group acquired a majority stake in ProSys Sampling Systems Limited from its co-founder and Treysa Limited. The transaction is a core component of IMA's international growth strategy, aiming to strengthen its "IMA Life" division by integrating specialized containment and sampling expertise. ProSys will continue to operate as an independent business from its headquarters in Ireland, with Michael McLoughlin remaining as Managing Director. This acquisition follows IMA's August 2024 purchase of Sarong's packaging divisions, further consolidating IMA's leadership in the advanced biopharmaceutical technology segment

Vivo Capital acquired a majority stake in Dutscher from LBO France. LBO France had acquired the asset in July 2020 from Five Arrows (Rothschild) for an enterprise value of EUR100-150M (investing EUR60M in equity). In this exit, LBO France achieved a net return multiple of ~2.5x. Interestingly, Five Arrows remains involved as the debt provider for this new LBO. The deal is expected to close in H1 2026.

Fagron acquired 100% of University Compounding Pharmacy for an Enterprise granting to Fagron a stronghold in California (a high-barrier market) and adds complementary therapeutic expertise (Urology) to its existing US portfolio (which includes Anazao). Fagron expects to realize significant synergies over the next 18-24 months by integrating UCP into its national platform.